Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Interview with Dr. Heikki Rauvala regarding Pivotal Advance: Analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin)

Interview with Dr. Heikki Rauvala regarding Pivotal Advance: Analysis of proinflammatory activity... Interview with Dr. Heikki Rauvala regarding Pivotal Advance: Analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin) Marco E. Bianchi San Raffaele University, Chromatin Dynamics Unit, Milan, Italy This work was selected as a Pivotal Advance because the paper shows that HMGB1, also co-discovered as amphoterin, in a fully purified state does not activate Toll-like receptors 2 and 4, but nevertheless still has considerable DNA-binding capac- ity, chemotactic effects, and developmental activities. Dr. Rauvala, you were the first to purify an extracellular protein that, as it turned out, is also a nuclear protein. How did you come across amphoterin? HR: In the mid 80s we were searching for neurite outgrowth promoting factors that would act on cortical neurons. This had been my major research goal for several years, since I had established my own lab after a postdoctoral experience in the US in 1979 –1980. Not many such factors were known, and the most interesting were fibroblast growth factors (FGFs). They were shown to regulate neuronal development, and to bind strongly to heparin and heparan sulfates. We homogenized young rat brains, and fractionated extracts on a heparin col- umn, where not many proteins would bind at high http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Leukocyte Biology Oxford University Press

Interview with Dr. Heikki Rauvala regarding Pivotal Advance: Analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin)

Journal of Leukocyte Biology , Volume 81 (1): 3 – Oct 12, 2006

Loading next page...
 
/lp/oxford-university-press/interview-with-dr-heikki-rauvala-regarding-pivotal-advance-analysis-of-n2p6CqOwYN

References (6)

Copyright
© 2007 Society for Leukocyte Biology
eISSN
1938-3673
DOI
10.1189/jlb.1306200
Publisher site
See Article on Publisher Site

Abstract

Interview with Dr. Heikki Rauvala regarding Pivotal Advance: Analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin) Marco E. Bianchi San Raffaele University, Chromatin Dynamics Unit, Milan, Italy This work was selected as a Pivotal Advance because the paper shows that HMGB1, also co-discovered as amphoterin, in a fully purified state does not activate Toll-like receptors 2 and 4, but nevertheless still has considerable DNA-binding capac- ity, chemotactic effects, and developmental activities. Dr. Rauvala, you were the first to purify an extracellular protein that, as it turned out, is also a nuclear protein. How did you come across amphoterin? HR: In the mid 80s we were searching for neurite outgrowth promoting factors that would act on cortical neurons. This had been my major research goal for several years, since I had established my own lab after a postdoctoral experience in the US in 1979 –1980. Not many such factors were known, and the most interesting were fibroblast growth factors (FGFs). They were shown to regulate neuronal development, and to bind strongly to heparin and heparan sulfates. We homogenized young rat brains, and fractionated extracts on a heparin col- umn, where not many proteins would bind at high

Journal

Journal of Leukocyte BiologyOxford University Press

Published: Oct 12, 2006

There are no references for this article.